167 related articles for article (PubMed ID: 19175384)
1. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Kopadze T; Döbert M; Leussink VI; Dehmel T; Kieseier BC
Eur J Neurol; 2009 Mar; 16(3):409-12. PubMed ID: 19175384
[TBL] [Abstract][Full Text] [Related]
2. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.
Kopadze T; Dehmel T; Hartung HP; Stüve O; Kieseier BC
Arch Neurol; 2006 Nov; 63(11):1572-8. PubMed ID: 17101825
[TBL] [Abstract][Full Text] [Related]
3. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
[TBL] [Abstract][Full Text] [Related]
4. Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.
Korsen M; Bragado Alonso S; Peix L; Bröker BM; Dressel A
PLoS One; 2015; 10(6):e0129182. PubMed ID: 26086440
[TBL] [Abstract][Full Text] [Related]
5. Oral Cladribine Impairs Intermediate, but Not Conventional, Monocyte Transmigration in Multiple Sclerosis Patients across a Model Blood-Brain Barrier.
Lin LY; Juillard P; Hawke S; Marsh-Wakefield F; Grau GE
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047460
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
[TBL] [Abstract][Full Text] [Related]
7. Cultured lymphocytes' mitochondrial genome integrity is not altered by cladribine.
Järvinen E; Suomi F; Stewart JB; Guala D; Valori M; Jansson L; Nieminen J; McWilliams TG; Tienari PJ
Clin Exp Immunol; 2023 Dec; 214(3):304-313. PubMed ID: 37860849
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Effects Associated with Cladribine Treatment.
Fissolo N; Calvo-Barreiro L; Eixarch H; Boschert U; Espejo C; Montalban X; Comabella M
Cells; 2021 Dec; 10(12):. PubMed ID: 34943995
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Janiec K; Wajgt A; Kondera-Anasz Z
Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
[TBL] [Abstract][Full Text] [Related]
10. Monomethylfumarate reduces in vitro migration of mononuclear cells.
Dehmel T; Döbert M; Pankratz S; Leussink VI; Hartung HP; Wiendl H; Kieseier BC
Neurol Sci; 2014 Jul; 35(7):1121-5. PubMed ID: 24504620
[TBL] [Abstract][Full Text] [Related]
11. Cladribine: mode of action and implications for treatment of multiple sclerosis.
Leist TP; Weissert R
Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
[TBL] [Abstract][Full Text] [Related]
12. CD95/Fas expression on peripheral blood T lymphocytes in patients with multiple sclerosis: effect of high-dose methylprednisolone therapy.
Petelin Z; Brinar V; Petravic D; Zurak N; Dubravcic K; Batinic D
Clin Neurol Neurosurg; 2004 Jun; 106(3):259-62. PubMed ID: 15177780
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
Grieb P; Stelmasiak Z
Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
[TBL] [Abstract][Full Text] [Related]
14. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
[TBL] [Abstract][Full Text] [Related]
15. Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.
Wiendl H; Schmierer K; Hodgkinson S; Derfuss T; Chan A; Sellebjerg F; Achiron A; Montalban X; Prat A; De Stefano N; Barkhof F; Leocani L; Vermersch P; Chudecka A; Mwape C; Holmberg KH; Boschert U; Roy S;
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411081
[TBL] [Abstract][Full Text] [Related]
16. Cladribine Reduces Trans-Endothelial Migration of Memory T Cells across an In Vitro Blood-Brain Barrier.
Ford RK; Juillard P; Hawke S; Grau GE; Marsh-Wakefield F
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294327
[TBL] [Abstract][Full Text] [Related]
17. Cladribine: mechanisms and mysteries in multiple sclerosis.
Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
[TBL] [Abstract][Full Text] [Related]
18. Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An
Dobreanu M; Manu DR; Mănescu IB; Gabor MR; Huţanu A; Bărcuţean L; Bălaşa R
Front Immunol; 2021; 12():743010. PubMed ID: 34970256
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
20. Cladribine for multiple sclerosis: review and current status.
Sipe JC
Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
